All In Biotech

Drug Trial Radar · NCT07108036

A Study to Assess Anktiva in Patients With Long Covid-19.

Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid.

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 14, 2025

Primary completion

Oct 2026

Study completion Oct 2026

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.

Conditions

  • Long COVID

Interventions

  • N-803 (IL-15 Superagonist)Drug

    N-803 administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
  2. Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
  3. Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
  4. Incidence of abnormal changes in safety laboratory tests (CBC and CMP).Time frame: Through the end of the study treatment period (approximately 75 days)
  5. Clinically important changes in vital signs.Time frame: Through the end of the study treatment period (approximately 75 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California - San Francisco

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.